G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
29 nov. 2023 20h37 HE
|
G1 Therapeutics
New data at the 2023 SABCS explore the long-term impact of trilaciclib on survival outcomes in patients with metastatic TNBC
G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
01 nov. 2023 06h30 HE
|
G1 Therapeutics
G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
27 oct. 2023 07h00 HE
|
G1 Therapeutics
Trilaciclib Reduces Hospitalizations and Myelosuppressive Events in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) and May Improve Survival
G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)
18 oct. 2023 08h00 HE
|
G1 Therapeutics
G1 Therapeutic's COSELA (trilaciclib) included in ASCO's updated SCLC treatment guidelines
G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 1, 2023
18 oct. 2023 07h30 HE
|
G1 Therapeutics
G1 Therapeutics to release 3Q23 financial results on November 1, 2023
G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium
16 oct. 2023 09h00 HE
|
G1 Therapeutics
G1 to present four posters at the 2023 ASCO Quality Care Symposium
G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
05 sept. 2023 11h00 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Communications Officer Will...
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 sept. 2023 16h15 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights
02 août 2023 06h30 HE
|
G1 Therapeutics
- Recognized Total Revenue of $42.4 Million, Including $11.1 Million in Net COSELA® (trilaciclib) Revenue - - Reiterated Expectation for Interim Overall Survival (OS) Analysis of Pivotal Phase 3...
G1 Therapeutics to Participate in Two August Investor Conferences
31 juil. 2023 14h30 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., July 31, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it will participate in two August...